Trial · NCT02021318
Results by group548
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 548
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Percentage of Participants With a Hb Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy | Roxadustat | 89.5 | Percentage of Participants | ||
| Percentage of Participants With a Hb Response to Treatment at Two Consecutive Visits During the First 24 Weeks of Treatment Without Rescue Therapy | Darbepoetin Alfa | 78.0 | Percentage of Participants | ||
| Change From Baseline in Hb to the Average Hb of Weeks 28 to 36 Without Rescue Therapy Within 6 Weeks Prior to and During This 8-Week Evaluation Period | Roxadustat | 1.848 | Standard Deviation 1.079 | g/dL | |
| Change From Baseline in Hb to the Average Hb of Weeks 28 to 36 Without Rescue Therapy Within 6 Weeks Prior to and During This 8-Week Evaluation Period | Darbepoetin Alfa | 1.839 | Standard Deviation 0.973 | g/dL | |
| Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) to the Average LDL-C of Weeks 12 to 28 | Roxadustat | -0.352 | Standard Deviation 0.772 | Millimoles per liter (mmol/L) | |
| Change From Baseline in Low Density Lipoprotein Cholesterol (LDL-C) to the Average LDL-C of Weeks 12 to 28 | Darbepoetin Alfa | 0.049 | Standard Deviation 0.705 | Millimoles per liter (mmol/L) | |
| Time to First Intravenous Iron Use | Roxadustat | Week 6 | 0 | 95% Confidence Interval 0 to 0 | Percentage of participants |
| Time to First Intravenous Iron Use | Darbepoetin Alfa | Week 6 | 2.8 | 95% Confidence Interval 0.9 to 4.6 | Percentage of participants |
| Time to First Intravenous Iron Use | Roxadustat | Week 12 | 1.3 | 95% Confidence Interval 0 to 2.5 | Percentage of participants |
| Time to First Intravenous Iron Use | Darbepoetin Alfa | Week 12 | 6.7 | 95% Confidence Interval 3.8 to 9.6 | Percentage of participants |
| Time to First Intravenous Iron Use | Roxadustat | Week 18 | 3.3 | 95% Confidence Interval 1.3 to 5.2 | Percentage of participants |
| Time to First Intravenous Iron Use | Darbepoetin Alfa | Week 18 | 9.2 | 95% Confidence Interval 5.8 to 12.6 | Percentage of participants |
| Time to First Intravenous Iron Use | Roxadustat | Week 24 | 4.3 | 95% Confidence Interval 2 to 6.5 | Percentage of participants |
| Time to First Intravenous Iron Use | Darbepoetin Alfa | Week 24 | 10.7 | 95% Confidence Interval 7.1 to 14.3 | Percentage of participants |
| Time to First Intravenous Iron Use | Roxadustat | Week 30 | 5.3 | 95% Confidence Interval 2.8 to 7.8 | Percentage of participants |
| Time to First Intravenous Iron Use | Darbepoetin Alfa | Week 30 | 12.6 | 95% Confidence Interval 8.7 to 16.5 | Percentage of participants |
| Time to First Intravenous Iron Use | Roxadustat | Week 36 | 6.7 | 95% Confidence Interval 3.9 to 9.6 | Percentage of participants |
| Time to First Intravenous Iron Use | Darbepoetin Alfa | Week 36 | 13.3 | 95% Confidence Interval 9.3 to 17.3 | Percentage of participants |
| Change From Baseline in Short Form-36 (SF-36) Physical Functioning (PF) Sub-Score to the Average PF Sub Score in Weeks 12 to 28 | Roxadustat | 0.913 | Standard Deviation 7.182 | Units on a scale | |
| Change From Baseline in Short Form-36 (SF-36) Physical Functioning (PF) Sub-Score to the Average PF Sub Score in Weeks 12 to 28 | Darbepoetin Alfa | 2.062 | Standard Deviation 7.838 | Units on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02021318/results